Clinical Report: Dana-Farber Cancer Institute Achieves Exceptional Stem Cell Transplant Outcomes

Overview

Dana-Farber Cancer Institute's adult and pediatric stem cell transplant programs received a +1 performance score from CIBMTR, indicating superior one-year survival rates compared to expected benchmarks. This marks the sixth consecutive year for the adult program and the second for the pediatric program, highlighting their exceptional clinical outcomes.

Background

Stem cell transplants are critical for treating various life-threatening conditions, including leukemias and immune disorders. The performance of transplant centers is essential for guiding patient care and ensuring optimal outcomes. The CIBMTR's annual survival reports provide a benchmark for evaluating transplant program effectiveness across the United States.

Data Highlights

Key Findings

• Both adult and pediatric programs at Dana-Farber received a +1 score from CIBMTR for exceeding expected survival rates.
• This is the sixth consecutive year for the adult program and the second for the pediatric program to achieve this score.
• Only eight out of 176 U.S. transplant centers were identified as overperforming, with Dana-Farber representing two of these centers.
• Dana-Farber is the only center among the 20 largest transplant centers in the U.S. to exceed statistical performance benchmarks for survival.
• The CIBMTR analysis adjusts for various factors, ensuring fair evaluation of each center's outcomes.

Clinical Implications

The recognition of Dana-Farber's programs underscores the importance of multidisciplinary teams in achieving high survival rates in stem cell transplants. Clinicians should consider the performance metrics of transplant centers when referring patients for these complex procedures.

Conclusion

Dana-Farber's exceptional performance in stem cell transplantation reflects its commitment to high-quality care and innovative research. These results serve as a benchmark for other transplant programs aiming to improve patient outcomes.

References

1. CIBMTR, Center for International Blood & Marrow Transplant Research, 2025 -- Annual Center-Specific Survival Reports
2. the asco post — How an Endowed Chair in Cord Blood Research Is Providing New Hope for Patients With High-Risk Leukemia
3. The ASCO Post — Dana-Farber Cancer Institute, Lifespan Partner to Advance Cancer Treatment and Expand Research
4. dana-farber — Dana-Farber’s Largest Single Gift Advances Planned Cancer Hospital for New England
5. dana-farber — Triplet Therapy Shows Promise for BPDCN, a rare blood cancer, in Dana-Farber Study
6. How an Endowed Chair in Cord Blood Research Is Providing New Hope for Patients With High-Risk Leukemia
7. Dana-Farber Cancer Institute, Lifespan Partner to Advance Cancer Treatment and Expand Research
8. Dana-Farber’s Largest Single Gift Advances Planned Cancer Hospital for New England
9. Methodology Employed for Annual Report on
10. Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendations | Bone Marrow Transplantation
11. Orca-T versus allogeneic hematopoietic stem cell transplantation (PRECISION-T): a multicenter, randomized phase 3 trial - ScienceDirect